(Q37442676)

20 August 2017

1 reference

title

Gastric cancer in the era of molecularly targeted agents: current drug development strategies (English)

1 reference

20 August 2017

Hendrik-Tobias Arkenau

series ordinal

1

1 reference

PubMed ID

19363621

20 August 2017

language of work or name

1 reference

11 April 2009

1 reference

Journal of Cancer Research and Clinical Oncology

20 August 2017

1 reference

20 August 2017

135

1 reference

20 August 2017

7

1 reference

20 August 2017

855-866

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-009-0583-7

20 August 2017

0 references

cites work

Histone deacetylase inhibitors in programmed cell death and cancer therapy

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-009-0583-7

Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-009-0583-7

Small molecule modulators of cyclin-dependent kinases for cancer therapy

21 January 2018

1 reference

12 December 2020

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

1 reference

12 December 2020

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

1 reference

12 December 2020

Epidermal growth factor

1 reference

12 December 2020

Flavopiridol. National Cancer Institute.

1 reference

12 December 2020

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

12 December 2020

Genetic pathways of two types of gastric cancer.

1 reference

12 December 2020

Aurora kinase family: a new target for anticancer drug.

1 reference

12 December 2020

Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma

1 reference

12 December 2020

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue

1 reference

12 December 2020

Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation

1 reference

12 December 2020

Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition.

1 reference

12 December 2020

Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis.

1 reference

12 December 2020

Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells

1 reference

12 December 2020

Mechanisms of disease: Inflammatory mediators and cancer prevention

1 reference

12 December 2020

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

1 reference

12 December 2020

Polo-like kinases (Plks) and cancer

1 reference

12 December 2020

c-Met expression in gastric cancer with liver metastasis

1 reference

12 December 2020

Gastric cancer cell lines induced by trichostatin A.

1 reference

12 December 2020

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

1 reference

12 December 2020

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

1 reference

12 December 2020

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases.

1 reference

12 December 2020

PI3K/Akt/mTOR pathway as a target for cancer therapy

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

1 reference

12 December 2020

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

1 reference

12 December 2020

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

12 December 2020

How bacteria could cause cancer: one step at a time.

1 reference

12 December 2020

Expression patterns of polo-like kinase 1 in human gastric cancer.

1 reference

12 December 2020

ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.

1 reference

12 December 2020

Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis

1 reference

12 December 2020

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

12 December 2020

Anticancer activities of histone deacetylase inhibitors

1 reference

12 December 2020

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

12 December 2020

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

12 December 2020

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas

1 reference

12 December 2020

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

1 reference

12 December 2020

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

1 reference

12 December 2020

Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery

1 reference

12 December 2020

Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines

1 reference

12 December 2020

Immunohistochemical detection of K-sam protein in stomach cancer

1 reference

12 December 2020

Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

1 reference

12 December 2020

Significance of expression of heat shock protein90α in human gastric cancer

1 reference

12 December 2020

Growth factor receptor interplay and resistance in cancer

1 reference

12 December 2020

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

12 December 2020

Cancer genetics of epigenetic genes

1 reference

12 December 2020

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

1 reference

12 December 2020

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

1 reference

12 December 2020

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

1 reference

12 December 2020

The ubiquitin-proteasome pathway and its role in cancer

1 reference

12 December 2020

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

1 reference

12 December 2020

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

1 reference

12 December 2020

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

1 reference

12 December 2020

A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer

1 reference

12 December 2020

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

1 reference

12 December 2020

Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis

1 reference

12 December 2020

Angiogenesis in health and disease

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis

1 reference

12 December 2020

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

1 reference

12 December 2020

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

1 reference

12 December 2020

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

1 reference

12 December 2020

The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells

1 reference

12 December 2020

Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells.

1 reference

12 December 2020

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

12 December 2020

Increased expression of histone deacetylase 2 is found in human gastric cancer.

1 reference

12 December 2020

10.1007/S00432-009-0583-7

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19363621